Advanced Medical Solutions Group plc

("AMS", the "Company" or the "Group")

            Directorate Change

            Liz Shanahan Appointed as an Independent Non-Executive Director

Winsford, UK: Advanced Medical Solutions Group plc (AIM: AMS), the world-leading specialist in tissue-healing technologies, is pleased to announce that, as the next step in its communicated plan to refresh the Non-Executive Directors on the Board, Liz Shanahan will be appointed as an Independent Non-Executive Director with immediate effect.

Liz is a life sciences entrepreneur with extensive experience advising leading global pharmaceutical and healthcare organisations on their communications. She is currently a Non-Executive Director of Inspiration Healthcare Group plc and Celadon Pharmaceuticals plc (previously Summerway Capital plc), both of which are AIM-listed. Most recently, she was a Non-Executive Director of UDG Healthcare plc, a company that was listed on the London Stock Exchange and a constituent of the FTSE 250 up until its £2.8 billion takeover in August 2021.

Until 2014, she was Global Head of Healthcare & Lifesciences at the NYSE-listed management consultancy, FTI Consulting Inc., which in 2007 acquired the communications business Santé Communications, founded by Liz in 1995. Liz is a Trustee of CW+, the charitable arm of Chelsea & Westminster Foundation Trust Hospital in London and a member of the organisation's Innovations Advisory Board. Alongside her Board appointments she is a business advisor and Executive coach.

Peter Allen, Chairman of AMS, said: "I am very pleased to welcome Liz to the Board of AMS, who brings with her significant experience in healthcare organisations, as well as specialist skills in communication and Executive coaching. She will be an extremely valuable addition to our Board."

Liz Shanahan commented: "I have been watching AMS's progress closely during my career and am very excited to be joining the Board of such a high-quality Company."

Liz will immediately join the Audit, Nomination and Remuneration Committees and will be responsible for Workforce Engagement in line with the UK Corporate Governance Code requirements. The composition of each of the Board Committees from 1 August 2022 is therefore confirmed as follows:

The following information is disclosed pursuant to Schedule Two, paragraph (g) of the AIM Rules for Companies:

Elizabeth Ann Shanahan (age 57) holds or has held Directorships and partnerships in the five years preceding her appointment at AMS as follows:

No further information in connection with her appointment is required to be disclosed under Schedule Two, paragraph (g) of the AIM Rules for Companies.

-End -

For further information, please visit www.admedsol.com or contact:

About Advanced Medical Solutions Group plc

AMS is a world-leading independent developer and manufacturer of innovative tissue-healing technology, focused on quality outcomes for patients and value for payers. AMS has a wide range of surgical products including tissue adhesives, sutures, haemostats, internal fixation devices and internal sealants, which it markets under its brands LiquiBand^®, RESORBA^®, LiquiBandFix8^® and Seal-G^®. AMS also supplies wound care dressings such as silver alginates, alginates and foams through its ActivHeal^® brand as well as under white label. Since 2019, the Group has made four acquisitions: Sealantis, an Israeli medical device company with a patent-protected sealant technology platform; Biomatlante, an established French developer and manufacturer of innovative surgical biomaterial technologies, Raleigh, a UK leading coater and converter of materials predominately for woundcare and bio-diagnostics products and AFS Medical, a specialist distributor of minimally invasive surgical devices based in Austria.

AMS's products, manufactured in the UK, Germany, France, Israel, the Netherlands, and the Czech Republic, are sold globally via a network of multinational or regional partners and distributors, as well as via AMS's own direct sales forces in the UK, Germany, the Czech Republic and Russia. The Group has R&D innovation hubs in the UK, Germany, France and Israel. Established in 1991, the Group has more than 700 employees. For more information, please see www.admedsol.com.